## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Joseph TSKOVITZ-ELDOR et al

Serial No.:

10/536,734

Filed:

May 27, 2005

For:

CULTURED HUMAN PANCREATIC ISLETS, AND

**USES THEREOF** 

Examiner: N/A

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 NOV 1 6 2005 W

Group Art Unit: 1645

Attorney

Docket: 29601

## INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin Moynihan

Martin

Registration No. 40,338

Dated: November 13, 2005

PTO/SB/08a (08-03)

Approved for use through 07/31/2006, OMB 0651-0031

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 2005 no pes are required to respond to a collection of information unless it contains a valid OMB control number

	Substitute for form 1449A/PTO  INFORMATION DISCLOSURE					Complete if Known			
_					Applicati	Application Number 10/536,734		6,734	
					Filing Da	ite	May :	May 27, 2005	
i	STATEMENT BY APPLICANT			First Nan	ned Inventor	Josep	h ITSKOVITZ-ELDOR et		
/ +	(use as many sheets as necessary)					al			
				Art Unit		1645			
					Examine	r Name	N/A		
Sheet		1	of	2	Attorney	Docket Number	2960	1	
			U.S.	PATENT	DOCUM	ENTS		<del></del>	
Examiner Initials*	Cite No. 1	Document Number  Number-Kind Code <sup>2 (if known)</sup>	Publication Date MM-DD-YYYY		Ap	Name of Patentee or plicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	1	US-6,280,718 08-28-2001		Kaufman et al.					
						<u>_</u>			
	<u> </u>				<del>                                       </del>	<del></del>			
					<del>-</del>				
				-					
								<u> </u>	
					-	<del>_</del>	-		
				-	+		1		
					<del>                                     </del>				
			FORE	CNDATE	NT DOC	INTERIO			
Examiner	Cite		FUREI		NT DOC	JWIENTS		Pages Columns Lines	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. 1	Foreign Patent Documents  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY		of Patentee or f Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6	
Examine	er				Date			
Signature					Considered		_	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1999 required to respond to a collection of information unless it contains a valid OMB control number.

	Su	bstitute for form 1449A/PTO	Complete	Complete if Known					
	Ģū.	ballate for form 1443AFTO	Application Number	10/536,734					
	INF	ORMATION DISCLOSURE	Filing Date	May 27, 2005					
		TEMENT BY APPLICANT	First Named Inventor	Joseph ITSKOVITZ- ELDOR et al					
(use as many sheets as necessary)			Group Art Unit	1645					
			Examiner Name	N/A					
Sheet	2	Of 2	Attorney Docket Number	29601					
		OTHER PRIOR ART – NON PATENT LIT	<b>ERATURE DOCUMENTS</b>						
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.							
	2	Hori et al. "Growth Inhibitors Promote Differentiation of Insulin-Producing Tissue							
	<del>  _ ·</del>	From Embryonic Stem Cells", PNAS, Early Ed.: 1-6.							
	3	Itkin-Ansari et al. "PDX-1 and Cell-Cell Contact Act in Synergy to Promote δ-Cell Development in a Human Pancreatic Endocrine Precursor Cell Line", Molecular Endocrinology, 14(6): 814-822, 2000.							
	4	Assady et al. "Insulin Production by Human Embryonic Stem Cells", Diabetes, 50: 1691-1697, 2001.							
	5	Bonner-Weir et al. "In Vitro Cultivation of Human Islets From Expanded Ductal							
	6	Tissue", PNAS, 97(14): 7999-8004, 2000.							
		Schuldiner et al. "Effects of Eight Growth Factors on the Differentiation of Cells Derived From Human Embryonic Stem Cells", PNAS, 97(21): 11307-11312, 2000.							
	7	Soria et al. "Insulin-Secreting Cells Derived From Embryonic Stem Cells Normalize Glycemia in Streptozotocin-Induced Diabetic Mice", Diabetes, 49: XXX-XXX, 2000.							
	8	Soria "In-Vitro Differentiation of Pancreatic Beta-Cells", Differentiation, 68: 205-219, 2001.							
	9	Lumelsky et al. "Differentiation of Embryonic Stem Cells to Insulin-Secreting							
	10	Structures Similar to Pancreatic Islets", Science, 292: 1389-, 2001.							
	10	Zhao et al. "Amelioration of Streptozotocin-Induced Diabetes in Mice Using Human Islet Cells Derived From Long-Term Culture In Vitro", Transplantation, 79(9): 1454-1460, 2002.							
			_	•					

1		
Signature	Considered	
Signature	Considered	1

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.